Search Results - "Tolaney, S.M."

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial by Kalinsky, K., Diamond, J.R., Vahdat, L.T., Tolaney, S.M., Juric, D., O'Shaughnessy, J., Moroose, R.L., Mayer, I.A., Abramson, V.G., Goldenberg, D.M., Sharkey, R.M., Maliakal, P., Hong, Q., Goswami, T., Wegener, W.A., Bardia, A.

“…Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC)…”
Get full text

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer by Waks, A.G., Cohen, O., Kochupurakkal, B., Kim, D., Dunn, C.E., Buendia Buendia, J., Wander, S., Helvie, K., Lloyd, M.R., Marini, L., Hughes, M.E., Freeman, S.S., Ivy, S.P., Geradts, J., Isakoff, S., LoRusso, P., Adalsteinsson, V.A., Tolaney, S.M., Matulonis, U., Krop, I.E., D’Andrea, A.D., Winer, E.P., Lin, N.U., Shapiro, G.I., Wagle, N.

“…Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with…”
Get full text

Prevalence and mutational determinants of high tumor mutation burden in breast cancer by Barroso-Sousa, R., Jain, E., Cohen, O., Kim, D., Buendia-Buendia, J., Winer, E., Lin, N., Tolaney, S.M., Wagle, N.

“…High tumor mutation burden (TMB) can benefit immunotherapy for multiple tumor types, but the prevalence of hypermutated breast cancer is not well described…”
Get full text

Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes by Tarantino, P, Tolaney, S M

Get more information

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer by Gennari, A., André, F., Barrios, C.H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S.A., Im, S.-A., Krug, D., Kunz, W.G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H.S., Saura, C., Schmid, P., Singer, C.F., Spanic, T., Tolaney, S.M., Turner, N.C., Curigliano, G., Loibl, S., Paluch-Shimon, S., Harbeck, N.

“…•This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing metastatic breast cancer.•It covers diagnosis, staging, risk…”
Get full text

Elacestrant: who are optimal candidates for the first oral SERD? by Lipsyc-Sharf, M., Tolaney, S.M.

Get full text

LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial by André, F., Nadal, J.C., Denys, H., Goel, S., Litchfield, L.M., Appiah, A., Chen, Y., Tolaney, S.M.

Get full text

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study by Harbeck, N., Rastogi, P., Martin, M., Tolaney, S.M., Shao, Z.M., Fasching, P.A., Huang, C.S., Jaliffe, G.G., Tryakin, A., Goetz, M.P., Rugo, H.S., Senkus, E., Testa, L., Andersson, M., Tamura, K., Del Mastro, L., Steger, G.G., Kreipe, H., Hegg, R., Sohn, J., Guarneri, V., Cortés, J., Hamilton, E., André, V., Wei, R., Barriga, S., Sherwood, S., Forrester, T., Munoz, M., Shahir, A., San Antonio, B., Nabinger, S.C., Toi, M., Johnston, S.R.D., O’Shaughnessy, J., Jimenez, M.M., Johnston, S., Boyle, F., Steger, G.G., Neven, P., Jiang, Z., Campone, M., Huober, J., Shimizu, C., Cicin, I., Wardley, A., Tolaney, S.M., Abuin, G.G., Zarba, J., Lim, E., Sant, P., Liao, N., Christiansen, B., Eigeliene, N., Martin-Babau, J., Ettl, J., Mavroudis, D., Chiu, J., Boer, K., Nagarkar, R., Paluch-Shimon, S., Moscetti, L., Sagara, Y., Kim, S.-B., Maciel, M.M., Tjan-Heijnen, V., Broom, R., Lacko, A., Schenker, M., Volkov, N., Sim Yap, Y., Coccia-Portugal, M., Ángel García Sáenz, J., Andersson, A., Chao, T.-Y., Gokmen, E., Harputluoglu, H., Berzoy, O., Patt, D., McArthur, H., Chew, H., Chalasani, P., Kaufman, P., Tedesco, K., Graff, S.L.

“…Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS)…”
Get full text

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer by Bardia, A., Tolaney, S.M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., Hamilton, E., Sharma, P., Recalde, S., Gil, E.C., Traina, T., O’Shaughnessy, J., Cortes, J., Tsai, M., Vahdat, L., Diéras, V., Carey, L.A., Rugo, H.S., Goldenberg, D.M., Hong, Q., Olivo, M., Itri, L.M., Hurvitz, S.A.

“…The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen…”
Get full text

54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) by Heong, V.Y.M., Marmé, F., Rugo, H.S., Tolaney, S.M., Bardia, A., Schmid, P., Verret, W., Valdez, T., Wang, H., Cortes, J.

Get full text

67P Clinicopathologic features of breast cancer patients eligible for adjuvant abemaciclib by Tarantino, P., Jin, Q., Mittendorf, E.A., King, T.A., Curigliano, G., Tolaney, S.M.

Get full text

389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) by Cortés, J., Marmé, F., Schmid, P., Rugo, H.S., Tolaney, S.M., Verret, W., Valdez, T., Huo, Y., Bardia, A.

Get full text

Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment by Tarantino, P., Tolaney, S.M., Curigliano, G.

Get full text

127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) by Miller, K.D., Emens, L.A., Tolaney, S.M., Hurvitz, S.A., Hamilton, E., Paton, V., Hannah, A.L., Boni, V.

Get full text

275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC) by Bardia, A., Punie, K., Barrios, C.H., Schneeweiss, A., Zhai, X., D.H. Huynh, Vaksman, N., Lai, C., Tolaney, S.M.

Get full text

276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC) by Tolaney, S.M., de Azambuja, E., Emens, L.A., Loi, S., Pan, W., Huang, J., Sun, S.W., Lai, C., Schmid, P.

Get full text

1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) by Rugo, H.S., Schmid, P., Tolaney, S.M., Dalenc, F., Marmé, F., Shi, L., Verret, W., Gharaibeh, M., Bardia, A., Cortés, J.

Get full text

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer by Tarantino, P., Viale, G., Press, M.F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H.J., Carey, L.A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A.K., Lebeau, A., Loibl, S., Modi, S., Mosele, M.F., Provenzano, E., Pruneri, G., Reis-Filho, J.S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S.J., Tolaney, S.M., Trapani, D., Vincent-Salomon, A., Wolff, A.C., Pentheroudakis, G., André, F., Curigliano, G.

“…Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from…”
Get full text

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer? by Giordano, A, Lin, N U, Tolaney, S M, Mayer, E L

Get more information

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study by Rugo, H.S., O’Shaughnessy, J., Boyle, F., Toi, M., Broom, R., Blancas, I., Gumus, M., Yamashita, T., Im, Y.-H., Rastogi, P., Zagouri, F., Song, C., Campone, M., San Antonio, B., Shahir, A., Hulstijn, M., Brown, J., Zimmermann, A., Wei, R., Johnston, S.R.D., Reinisch, M., Tolaney, S.M.

“…In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk,…”
Get full text